Arvanil
TRPV1 channel activator / Arvanil is a non-pungent capsaicin analog with antinociceptive and anti-inflammatory effects in vivo.1 It is an agonist at TRPV1 as well as CB1 (Ki = 0.25 – 0.52 μM), but not CB2.2,3 Caused high mitochondrial calcium flow in hepatocellular carcinoma cells, ultimately leading to ferroptosis.4 It induced FADD-dependent apoptosis in lymphoid Jurkat T-cells.5 Neuroprotective in rat excitotoxicity model.6
Biochemicals & reagents
128007-31-8
Vanillylarachidonamide
1 Janusz et al. (1993), 1. Analogs of capsaicin with antinociceptive and antiinflammatory activity; J. Med. Chem. 36 2595 2 Lim et al. (2022), Highly Efficient Real-Time TRPV1 Screening Methodology for Effective Drug Candidates; ACS Omega 7 36441 3 Di Marzo et al. (1998), Interactions between synthetic vanilloids and the endogenous cannabinoid system; FEBS Lett. 436 449 4 Deng et al. (2024), Arvanil induces ferroptosis of hepatocellular carcinoma by binding to MICU1; Cancer Gene Ther. 31 148 5 Sancho et al. (2003), The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway; Br. J. Pharmacol. 140 1035 6 Veldhuis et al. (2003), Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: the role of vanilloid receptors and lipoxygenases; J. Neurosci. 23 4127
-20°C
TARGET: Ion channel; GPCR -- PATHWAY: Apoptosis inducer; Cation channel; Calcium signaling; Mitochondrial function; Cell cycle -- RESEARCH AREA: Neuroscience; Cell death -- DISEASE AREA: Neurodegeneration; PainCancer; Inflammation